New treatment for a specific T-cell lymphoma type
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests chidamide plus CHOP chemotherapy in people who have not received any prior treatment for a certain type of peripheral T-cell lymphoma. The study aims to shrink the lymphoma and improve outcomes while checking for side effects and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18–75, and male or female
- Your biopsy confirms peripheral T-cell lymphoma with a “follicular helper T-cell” type, such as AITL or follicular T-cell lymphoma (FTCL)
- You have never had chemotherapy, radiation, or other lymphoma treatments before
- You cannot have (or do not want) an autologous stem cell transplant (using your own cells)
- There is at least one measurable or evaluable lymphoma area on scans (PET/CT, CT, or MRI) and your scan findings meet the study rules
- You are generally strong enough for treatment (ECOG 0–2) and your blood counts and organ lab tests meet required thresholds
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
This trial tests adding chidamide to standard chemotherapy (R-CHOP) for people newly diagnosed with a specific subtype of diffuse large B-cell lymphoma. It may help improve outcomes for those whose cancer cells have high levels of MYC and BCL2 proteins.
This trial studies whether adding chidamide to a combination chemotherapy plan (azacitidine, liposomal mitoxantrone, and prednisone) works better for people newly diagnosed with nodal T-follicular helper (TFH) cell lymphoma. It’s testing a treatment strategy after diagnosis to improve disease control and outcomes.
This trial is testing a combination of two targeted drugs – chidamide (an HDAC inhibitor) and golidocitinib (a JAK inhibitor) – for people with peripheral T-cell lymphoma that has come back or hasn't responded to prior treatments. The goal is to see if this combination can shrink tumors or stop the cancer from growing.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
This trial studies chidamide (a prescription medicine) in people with diffuse large B-cell lymphoma that has come back or did not respond to at least one prior treatment. It may help shrink tumors and improve disease control for eligible patients.
Hear when a new Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.